Prevalence and Incidence of Hereditary Angioedema: A Systematic Literature Review Authors: Timothy J. Craig, Marc A. Riedl, Tukisa D. Smith, Ellen Kasireddy, Otto L. T. Lam, Monica R. McClain Published: 2026 ABSTRACT AbstractIntroductionPrior reports on the global prevalence of hereditary angioedema (HAE) have varied widely, and it remains uncertain as to what extent such variation can be attributed to regional differences. More accurate estimates of HAE prevalence can potentially raise awareness among clinicians and reduce diagnostic delay. This systematic literature review identified studies reporting on HAE prevalence, with the aim of generating pooled global/regional estimates.MethodsRelevant studies were identified through a systematic search of MEDLINE® and Embase (inception to June 21, 2024). Study selection, data extraction, and quality assessment were performed in duplicate by two independent reviewers; 5,225 studies were screened, with 41 publications (pertaining to 40 unique studies) being included.ResultsMost studies were conducted in Europe (n = 22); other regions included Northern Eurasia (n = 1), North (n = 3) and South America (n = 1), Africa (n = 1), Middle East (n = 1), East Asia (n = 6), and Oceania (n = 1). Diagnostic methodology varied greatly, with a minority of studies citing an established guideline. Pooled diagnosed annual prevalence estimates (95% confidence interval) were 1.31 per 100,000 (0.83–2.08; type I HAE), 0.20 per 100,000 (0.14–0.29; type II HAE), 0.06 per 100,000 (0.01–0.40; HAE with normal C1-inhibitor [INH]), and 1.70 per 100,000 (1.58–1.83; combined types). Pooled estimates by region were 1.43 per 100,000 (0.99–2.08) and 1.64 per 100,000 (1.02–2.64) in North America and Europe, respectively, which were higher than individual estimates from the other regions.ConclusionThis review determined pooled, minimal diagnosed annual prevalence estimates for type I HAE, type II HAE, HAE-nC1-INH, and type I/II/nC1-INH combined. The pooled estimate for European countries was relatively higher than that for North American countries, as well as individually reported estimates in other regions. Nevertheless, valid comparisons across countries were hindered by a large degree of heterogeneity in data sources and diagnostic methodology. Additional, high-quality studies using standardized diagnostic methods are required to elucidate whether regional differences can be truly attributed to ethnic differences in phenotypic and genotypic variability. Introduction Hereditary angioedema (HAE) is a rare genetic disorder primarily characterized by disturbances in the bradykinin pathway, leading to increased vascular permeability and extravascular fluid accumulation. Mutations in the SERPINGI gene, which is responsible for C1-inhibitor (C1-INH) synthesis, underlie both type I (deficient C1-INH level) and type II (impaired C1-INH function) HAE [1, 2]. A third type of HAE with normal C1-INH activity (nC1-INH; formerly referred to as type III) is attributed to mutations in other genes, including F12, PLG, ANGPT1, KNG1, MYOF, and HS3OST6 [3]. The cardinal symptom of HAE is non-inflammatory cutaneous and mucosal edema, but the presentation can vary (e.g., abdominal pain, ascites, facial edema) depending on the affected body region [4]. Pharyngeal/laryngeal edema is particularly concerning as this can lead to asphyxiation, historically a cause of death in one-third of individuals with HAE due to C1-INH deficiency [5]. HAE is a lifelong condition with substantial detrimental impacts on daily function, productivity, and quality of life [6], underscoring the importance of early diagnosis and appropriate management with on-demand therapy and long-term prophylaxis [7]. Nevertheless, HAE is frequently associated with diagnostic delays exceeding 10 years, indicating high rates of misdiagnosis [8], resulting in unnecessary social and psychological burden. The global prevalence of HAE has been shown to vary widely, ranging from 0.08 to 3.35 per 100,000 [9]. It remains uncertain as to what extent such variation can be attributed to regional differences in health care provider awareness, underlying ethnic differences across countries, or heterogeneity in sampling and diagnostic methodology. Prior reviews on HAE prevalence have often lacked pooled global and regional estimates [8, 10], or failed to account for study quality and HAE type when determining such estimates [9]. More accurate estimates of HAE prevalence and a deeper insight into differences across regions can potentially raise awareness among clinicians, thereby reducing diagnostic delay, guide screening strategies, reveal disparities in diagnosis and care, facilitate planning and resource allocation, and support patient advocacy in the context of public health and policy. Therefore, the objective of this systematic literature review was to complement and extend the existing literature by identifying studies reporting the prevalence of HAE and generating both global and regional pooled, evidence-based estimates for this condition. Methods This systematic literature review followed standard methodologies recommended by the Cochrane Handbook for Systematic Reviews of Interventions [11] and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [12]; a PRISMA checklist has been included as an online supplementary material. Predefined search strategies (online suppl. material – Table S1; for all online suppl. material, see https://doi.org/10.1159/000553023) were used for identifying relevant studies from MEDLINE® and Embase (via OvidSP) from database inception to June 21, 2024. Bibliographies of published literature reviews were also searched. This review was not registered in a public database. A protocol was prepared for internal use, and no amendments were made after initiation of the review. Study eligibility criteria were based on the CoCoPop framework (Condition, Context, Population) [13]. Studies reporting the prevalence and/or incidence of any type of HAE were included; studies reporting on acquired angioedema or published in non-English languages were excluded. Study selection, data extraction (for relevant study and population characteristics, prevalence/incidence outcomes), and quality assessment (Joanna Briggs Institute [JBI] Checklist for Prevalence Studies) [14] were performed by two independent reviewers. Any discrepancies were resolved through discussion; consensus was achieved via the input of a third reviewer, where necessary. Diagnosed prevalence estimates were synthesized, and a pooled analysis alongside generated forest plots was conducted where feasible. Meta-analyses used a random-effects model (restricted maximum likelihood estimator) via the metafor package (v4.6-0) in R statistical software. Prevalence rates were pooled on the logit scale, then plotted on the original prevalence scale. When confidence intervals (CIs) were reported, standard errors were derived directly, calculated from the CI for each study; otherwise, they were calculated from the number of cases and population size under study. Results Study Selection A total of 6,578 abstracts were identified from database searches prior to de-duplication and 19 abstracts from manual searches. Title and abstract screening were conducted for 5,225 studies, followed by full-text screening of 44 studies. Finally, 41 publications representing 40 unique studies were included (shown in Fig. 1) [15–51]. PRISMA flow diagram illustrating study selection process. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Study Characteristics Of the 40 included studies, most were published after 2010 (16 in 2010–2019, 18 in 2020, or later) (online suppl. material – Table S2). The majority were conducted in Europe (n = 22), with Italy (n = 3) and the United Kingdom (UK) (n = 2) most frequently reported. Other regions included Northern Eurasia (Russia [n = 1]), North America (United States [US] [n = 2], Mexico [n = 1]), South America (Colombia [n = 1]), Africa (South Africa [n = 1]), Middle East (Saudi Arabia [n = 1]), East Asia (Taiwan [n = 2], South Korea [n = 2], Japan [n = 1], China [n = 1]), and Oceania (Australia [n = 1]). Study time frames ranged from single-year (n = 11) to multi-year periods up to 20 years (n = 17) or were not reported (n = 12). Populations were derived from one or multiple sources per study: clinical centers (n = 13), hospital registries (n = 12), surveys (n = 9), national health databases (n = 7), and unspecified sources (n = 7). Only 15 studies cited an established diagnostic guideline. The most frequently referenced documents were from the C1 Esterase Inhibitor Deficiency Workshop (2004) [26] (n = 6), followed by the International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema (2010) [52] (n = 3); World Allergy Organization/European Academy of Allergy and Clinical Immunology (2021) (n = 3) [53]; Hereditary Angioedema International Working Group 2014 [54] (n = 1) and 2012 [55] (n = 2); Primary Immunodeficiency Association (2005) [56] (n = 1); Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (2008) [57] (n = 1); International Union of Immunological Societies Expert Committee (2020) [58] (n = 1); and the World Health Organization Scientific Group for primary immunodeficiency diseases (1997) [59] (n = 1). Most studies (n = 28) reported using laboratory criteria for diagnosing HAE. However, only 16 studies specified a C1-INH antigenic and/or functional level threshold for diagnosis; a threshold of 50% was most frequently used (n = 12). Notably, 4 studies utilized a threshold of 40% for either functional (n = 3) and/or antigenic (n = 1) C1-INH levels. Studies that did not specify the use of laboratory criteria included those that used diagnostic codes in registries (n = 2), prescription claims databases (n = 1), a combination of both methods (n = 1), or otherwise did not provide additional details (n = 8). Nevertheless, no studies explicitly reported a sole reliance on clinical signs/symptoms for diagnosis. Repeat testing for diagnostic confirmation (n = 17) and the use of specific laboratory assays (n = 16) were reported by a minority of studies. Details on other diagnostic parameters, such as sample handling/storage conditions (n = 5), were scarcely reported. Genetic analysis (primarily on SERPING1) was reported in 19 studies. Nine studies identified novel SERPING1 mutations. All studies evaluating HAE-nC1-INH documented the use of genetic analysis; specific genes included F12 (n = 4), ANGPT1 (n = 2), PLG (n = 2), and KNG1 (n = 1). Population Characteristics Most studies reported on multiple HAE types. Type I/II was most frequently reported (n = 25), followed by type I (n = 18), type II (n = 14), type I/II/nC1-INH (n = 5), and HAE-nC1-INH (n = 5) (online suppl. material – Table S3). Eight studies did not specify the type of HAE of included participants. Studies mainly pertained to mixed age-groups (n = 28). Four studies limited their inclusion to adults; one study exclusively included children (<12 years of age). Among studies that documented participant sex (n = 28), the majority (n = 23) reported a predilection toward females across HAE types, with this being more pronounced in cases of HAE-nC1-INH. Age at symptom onset was noted in 17 studies, with mean estimates ranging from 10 years (type I/II; Serbia) [32] to 44.5 years (type II; Portugal) [31]. Symptoms typically first appeared during childhood/adolescence, with only 6 studies reporting estimates >18 years of age: 18.4 (mean, type I/II; Austria) [19], 20.8 (mean, type I; Taiwan) [37], 21 (median, F12-HAE; Italy) [27], 23 (median, unknown-HAE; Italy) [27], 23.9 (mean, type I/II/nC1-INH; Canary Islands) [21], 28.4 (mean, type I/II; South Korea) [47], and 44.5 (mean, type II; Portugal) [31]. Among studies reporting on diagnostic delay (n = 19), most documented an estimate of ≥10 years (n = 14), with the longest delay (mean: 26.0 years, type I/II) observed in Türkiye [39]. Shorter diagnostic delays of <10 years were observed in the UK (median: 2 years, unspecified type) [41, 42], US (mean: 6 years, type I/II/nC1-INH) [15], South Korea (mean: 7.8 years, type I/II) [47], Canary Islands (mean: 8.1 years, type I/II/nC1-INH) [21], and Taiwan (mean: 8.45 years, type I) [37]. The proportion of asymptomatic cases (n = 15) generally ranged from 0% [30, 32, 44, 49] to 10% [32], with exceptions being higher estimates in Taiwan (42.1%; type I) [37], Spain (13.7%; type I/II) [35], and the Canary Islands (12.5%; type I/II/nC1-INH) [21]. Notably, Bova et al. [27] reported that all males with F12-HAE were asymptomatic. Diagnosed Prevalence of HAE HAE prevalence was reported in all 40 studies (online suppl. material – Table S4), of which 8 were included to generate pooled estimates by type of HAE based on study quality, accuracy of estimates, and population characteristics (shown in Fig. 2). Pooled annual prevalence rates by HAE type were 1.31 per 100,000 for type I, 0.20 per 100,000 for type II, 1.62 per 100,000 for type I/II, 0.06 per 100,000 for nC1-INH, and 1.70 per 100,000 for type I/II/nC1-INH combined. Forest plot with pooled estimates of diagnosed annual prevalence (per 100,000) by HAE type. CI, confidence interval; nC1-INH, normal C1-inhibitor level and function; UK, United Kingdom; US, United States. †Riedl 2023 corrected for sampling bias using two approaches, resulting in two prevalence estimates. The mean value of these estimates was used for pooling. Eight studies were included to generate pooled estimates by region (shown in Fig. 3). Pooled diagnosed annual prevalence rates (for HAE type I/II, I/II/nC1-INH, or unspecified type) were 1.43 per 100,000 in North America and 1.64 per 100,000 in Europe. Prevalence rates reported by studies conducted in East Asia could not be pooled as only 1 study [45] provided a clear timeframe reference. Nevertheless, rates in this region (online suppl. material – Table S4) were consistently numerically lower relative to pooled rates for Europe and North America (shown in Fig. 3). Rates in other regions (Russia, Colombia, Saudi Arabia, South Africa, and Australia) were also relatively lower than the pooled European and North American estimates. Forest plot with pooled estimates of diagnosed annual prevalence (per 100,000) by region. CI, confidence interval; nC1-INH, normal C1-inhibitor level and function; UK, United Kingdom; US, United States. †Riedl 2023 corrected for sampling bias using two approaches, resulting in two prevalence estimates. The mean value of these estimates was used for pooling. Diagnosed Incidence of HAE Annual HAE incidence was only reported in 3 studies: 0.074 per 100,000 (HAE type I/II) in Slovakia [33], 0.16 per 100,000 (HAE type I/II) in Finland [23], and 0.34 per 100,000 (unspecified HAE type) in Germany [24] (Table 1). Table 1.Reported incidence rates across included studiesStudyStudy population descriptionStudy population sizeCountryTime frameHEA typeReported rateYearly incidence rate (per 100,000)Sandberg, 2024 [23]OverallNR (Finland)Finland2010–2021Type I/II0.16 per 100,000 (mean)0.16Prenzel, 2023 [24]Children (0–11 years)9,080,071 (children 0–11 years, with SHI)Germany 2016–2021 Unspecified 0.35 per 100,000 per year † 0.35 † 8,810,951 (children 0–11 years, with SHI)20160.32 per 100,000 per year0.328,946,821 (children 0–11 years, with SHI)20170.4 per 100,000 per year0.409,076,510 (children 0–11 years, with SHI)20180.23 per 100,000 per year0.239,172,385 (children 0–11 years, with SHI)20190.4 per 100,000 per year0.409,236,880 (children 0–11 years, with SHI)20200.43 per 100,000 per year0.439,236,880 (children 0–11 years, with SHI)20210.29 per 100,000 per year0.29Overall72,699,180 (total population with SHI in Germany) 2016–2021 0.34 per 100,000 per year † 0.34 † 71,449,138 (total population with SHI in Germany)20160.52 per 100,000 per year0.5272,258,037 (total population with SHI in Germany)20170.34 per 100,000 per year0.3472,802,098 (total population with SHI in Germany)20180.28 per 100,000 per year0.2873,009,237 (total population with SHI in Germany)20190.33 per 100,000 per year0.3373,357,859 (total population with SHI in Germany)20200.28 per 100,000 per year0.2873,318,711 (total population with SHI in Germany)20210.27 per 100,000 per year0.27Markocsy, 2024 [33]Overall5,449,270 (Slovakia, 2021 census)Slovakia2021Type I/II1:1,360,0000.074EAACI, European Academy of Allergy and Clinical Immunology; ICD-O, International Classification of Diseases for Oncology; HAE, hereditary angioedema; NR, not reported; SHI, statutory health insurance; WAO, World Allergy Organization; WHO, World Health Organization. †Calculated from separately reported time periods. Reported incidence rates across included studies EAACI, European Academy of Allergy and Clinical Immunology; ICD-O, International Classification of Diseases for Oncology; HAE, hereditary angioedema; NR, not reported; SHI, statutory health insurance; WAO, World Allergy Organization; WHO, World Health Organization. †Calculated from separately reported time periods. Study Quality Assessment Of the 41 included publications, 8 could not be formally assessed due to lack of access to full-text articles or non-English language full-text publications. Variable quality was observed across domains for the remaining 33 studies (shown in Fig. 4; online suppl. material – Table S5). Most studies clearly defined the sample frame and used appropriate sampling methods (question [Q]1 and Q2: 60.6%, “yes”), although a substantial proportion did not (Q1: 36.4%; Q2: 30.3%). Sample size justification and descriptions of study subjects and settings were generally adequate (Q3: 69.7%; Q4: 78.8%). Fewer studies reported sufficient coverage of the identified sample (Q5: 39.4%). Valid and reliable methods for condition assessment were commonly reported (Q6 and Q7: 87.9%). In contrast, statistical analysis methods were often inadequately described (Q8: 69.7%, “no”), primarily due to missing denominators or time frames. Response rates were suboptimally reported, with adequate information provided in only 42.4% of studies (Q9). While many studies demonstrated overall strengths in sampling and measurement validity, limitations in data coverage, statistical reporting, and response rate handling potentially affected the reliability of prevalence estimates. Based on these assessments, 9 studies were included in the pooled analysis, 19 were excluded, and 13 (including the 8 not assessed) were classified as “seek further information” due to insufficient data for an inclusion decision. Summary of quality assessment (JBI Checklist for Prevalence Studies). Questions in the assessment included the following: (1) Was the sample frame appropriate to address the target population? (2) Were study participants sampled in an appropriate way? (3) Was the sample size adequate? (4) Were the study subjects and the setting described in detail? (5) Was the data analysis conducted with sufficient coverage of the identified sample? (6) Were valid methods used for the identification of the condition? (7) Was the condition measured in a standard, reliable way for all participants? (8) Was there appropriate statistical analysis? (9) Was the response rate adequate, and if not, was the low response rate managed appropriately? JBI, Joanna Briggs Institute. Discussion This review evaluated HAE prevalence, documenting pooled annual diagnosed estimates of 1.31/100,000 for type I, 0.20/100,000 for type II, 1.62/100,000 for type I/II, 0.06/100,000 for HAE-nC1-INH, and 1.70/100,000 for type I/II/nC1-INH combined. These estimates are similar to those described by Guan et al. [8] and Aygören-Pürsün et al. [10], which ranged from 0.13 to 1.6 cases/100,000 (across eight included studies) and 1.1 to 1.6/100,000 (across six studies), respectively, as well as Fisch et al. [9], who reported a global pooled estimate of 1.22 (95% CI: 0.91, 1.53)/100,000. The pooled diagnosed prevalence for combined HAE types (I/II, I/II/nC1-INH, or unspecified) by region was numerically higher in Europe (1.64/100,000) than in North America (1.43/100,000). This may possibly be attributed to relatively more rigorous screening methods in Europe, with all 5 pooled studies reporting the use of either an established guideline, specific C1-INH antigenic/functional level thresholds, repeat testing, and/or genetic testing for HAE diagnosis. In contrast, none of the pooled studies from North America reported on these parameters, with the exception of one study [17] that utilized genetic analysis; this was, however, only performed in a small subset of patients within a larger mixed-methods approach that synthesized data across national health system databases, physician surveys, and published literature in an epidemiological model. Therefore, the difference in HAE prevalence between North America and Europe should be interpreted with caution, owing to the large and overlapping CIs observed. Diagnosed prevalence estimates in other regions were comparatively lower than the pooled North American and European estimates. Lower estimates reported in Russia, Colombia, Saudi Arabia, and South Africa may be attributed to the data source utilized. For example, investigations in Saudi Arabia [49] and South Africa [50] were only based on a single center; Coovadia et al. [50] ascribed the low prevalence to underdiagnosis and lack of referral (especially for patients in rural areas) for evaluation. Similarly, the use of national claims data may have contributed to a lower prevalence in Colombia [18] due to underrepresentation of underserved populations (e.g., rural/marginalized areas), despite a universal healthcare system. Notably, a recently published US study [60] (beyond the date restrictions of this review) utilizing a claims-based algorithm with expert physician assessment reported a higher annual prevalence (all-type HAE) of 1.84/100,000 (in 2020) relative to our global pooled rate. Laboratory test results were not assessed, and restriction to individuals with a continuous health plan may be a contributing factor. Mukhina et al. [43] acknowledged an underreporting rate of 15–20% for all primary immunodeficiencies in the Russian registry (which includes HAE under complement deficiencies according to the European Society for Immunodeficiencies criteria, similarly to International Classification of Diseases [ICD]-10 codes in US studies), owing to the lack of mandatory reporting. Prevalence rates in East Asia (China, Taiwan, South Korea, Japan) were consistently numerically lower compared to the pooled global, European, and North American rates. This was also in line with the results of Li et al. [61], who reported low prevalence rates across Japan (0.02 per 100,000), China (0.04 per 100,000), Taiwan (0.22 per 100,000), South Korea (0.29 per 100,000), and Singapore (0.33 per 100,000), although this study was excluded from the present review due to the rates being derived from “professional judgment and estimates” rather than “accurate statistics,” reflecting limited availability of underlying patient level data. Although lower prevalence in this region may be due to a relatively lower awareness and diagnosis rate among physicians, this conflicts with evidence demonstrating a high level of knowledge of HAE and its management in East Asian countries such as South Korea [62]. Other potential contributory factors (e.g., delayed symptom onset [63], milder symptoms, greater proportion of asymptomatic cases [37, 47, 64], cultural differences) may be more relevant in East Asian populations. Such phenotypic heterogeneity may in turn be related to underlying genotypic variation among different ethnic groups [37]. Indeed, prior studies have suggested that certain mutations may be associated with increased disease severity and earlier onset [32]. Emerging prevalence studies from other Asian countries outside East Asia, including a recently published report from India [65], underscore the increasing availability of epidemiologic data from non-Western settings. Although this study was published outside the prespecified search window and could not be formally evaluated here, it reflects a growing effort to characterize HAE prevalence beyond Europe and North America and reinforces the need for region-specific, methodologically robust investigations. Several trends were observed in terms of patient characteristics. First, there was a predilection toward females, across HAE types. Although an equal representation of sexes would be expected for a classic autosomal dominant pattern of inheritance (e.g., via a mutated copy of SERPING1 or F12), females are more likely to be symptomatic and experience more frequent and severe attacks due to hormonal factors. This has been linked to fluctuations in estrogen during the different female life stages (e.g., childhood, puberty, menses, pregnancy) [66] and the use of estrogen-containing contraceptives [36], these effects being particularly evident in HAE-nC1-INH [67]. Second, a prolonged interval of ≥10 years between initial symptom onset and diagnosis was reported by most studies, with the longest diagnostic delay (mean: 26.0 years) documented in Türkiye. This suggests that many symptomatic patients are misdiagnosed, or avoid diagnosis for cultural reasons, and receive inappropriate treatment, thus leading to unnecessary and protracted periods of pain and discomfort, as well as social, psychological, and economic burden. Diagnostic delay has been mainly linked to a general lack of awareness of this condition, due to its rarity, in the medical community [39]. Diagnostic avoidance and underreporting may also be due to cultural and social stigma associated with genetic conditions in general, particularly in low- to middle-income countries. For example, patients may fear social isolation from their extended family and community, as well as stigmatization in relation to marital eligibility. A reluctance to seek medical support may be further compounded by lack of access to available therapies in these regions [68]. As symptom onset often occurs in childhood/adolescence, increased educational interventions should be targeted within the field of pediatrics [22]. While diagnostic delay did not differ greatly among different HAE subtypes, HAE-nC1-INH diagnosis may be further hampered by the lack of definitive laboratory assays and limited access to genetic tests for diagnostic confirmation [15]. Third, the proportion of asymptomatic patients generally ranged from 0 to 10%, encompassing the reported estimate of 5% [26]. The proportion of asymptomatic type I cases (42.1%) observed in Taiwan was much higher compared to Western countries, which likely contributes to the lower HAE prevalence in East Asia [37]. This indicates a potentially large number of undiagnosed cases, highlighting the importance of screening family members of patients with a confirmed diagnosis. Further studies are required to provide additional insight into genotypic and phenotypic variation among different ethnic groups. In terms of diagnostic methodology, most studies (n = 28) explicitly reported the use of laboratory criteria, thus decreasing the risk of underestimating true HAE prevalence via a sole reliance on clinical signs and symptoms. However, only a minority of studies (n = 15) cited an established guideline for HAE diagnosis, and only 16 studies specified a threshold for C1-INH antigenic and/or functional levels. Notably, 4 studies utilized a lower cutoff (<40%) than the most frequently utilized threshold of <50%, potentially underestimating the number of cases. Nevertheless, it must be acknowledged that such presumed thresholds do not fully capture individuals who exhibit functional C1-INH levels >50% but still experience regular attacks. Reported prevalence may also be influenced by the type of laboratory assay used. For example, the positive predictive value for diagnosing C1-INH functional deficiency is lower with the chromogenic assay (36%) compared to the enzyme-linked immunosorbent assay (92%), while the former test has a superior negative predictive value (99% vs. 89%) [26, 69]. Notably, most of the included studies (n = 10) with details on functional tests used the chromogenic assay. Guidelines often highlight the importance of repeat testing to mitigate the risk of erroneous results, particularly false-positives, owing to the rarity of the condition [26, 52, 53, 56, 69], although the avoidance of false-negative results may be more critical since acute episodes can be life-threatening and fail to respond to conventional treatments for edema (e.g., antihistamines, corticosteroids) [22]. C1 Esterase Inhibitor Deficiency Workshop (2004) [26] guidelines specifically recommend that a diagnosis should be confirmed using 2 blood samples drawn 1–3 months apart, although the more recent 2020 US Hereditary Angioedema Association guidelines state that further repeated testing is not required once C1-INH deficiency has been established [70]. The 2021 World Allergy Organization/European Academy of Allergy and Clinical Immunology guidelines specify repeated testing in a certified laboratory for diagnostic confirmation, but further repeated testing is not required following an established diagnosis [53]. A minority of studies (n = 17) mentioned repeat testing for diagnostic confirmation, either explicitly in their methodology or through citation of relevant guidelines. Details on sample handling and storage conditions were infrequently reported (n = 5). This is pertinent, as C1-INH is labile, and functional activity rapidly decays in unfrozen samples. Conversely, sample storage at 0°C may lead to cold activation of the kallikrein-kinin pathway, leading to increased C1-INH consumption and false-positive results [71]. Cold activation may also only cause minor C1-INH consumption, leading to borderline results. Such sample mishandling (in conjunction with unexplained angioedema symptoms) would be especially problematic for HAE-nC1-INH, which is primarily diagnosed by first excluding C1-INH deficiency and mast cell-mediated angioedema (by demonstrating unresponsiveness to high-dose second-generation H1 antagonists plus montelukast [if warranted] and omalizumab including 600 mg every 2 weeks, if needed), followed by targeted gene sequencing [3]. Genetic analysis was only reported in 19 studies. Most guidelines [52, 54] suggest that genetic testing is often not necessary for diagnosing HAE type I or II, particularly in cases with a positive family history, with this approach typically being limited to infants within 1 year after birth. Nevertheless, genetic testing may also facilitate diagnosis in inconclusive/borderline cases. For example, a diagnosis of type II may be missed in cases with borderline C1-INH functional levels and mild symptoms, despite the determination of both C1-INH antigenic and functional levels. Cases with normal functional levels due to successful treatment may also be missed if this information is not accounted for in the laboratory [26]. Zanichelli et al. [28] reported that a diagnosis of HAE type I was made when both functional and antigenic C1-INH were ≤50% of normal, whereas type II was determined when functional C1-INH was ≤50% and antigenic levels were >50%. They noted that 2 patients with C1-INH antigen levels “slightly” above 50% should have been diagnosed with type II; however, these patients were classified with type I due to their family history. Likewise, Zanichelli et al. (2015) [28] also commented that 12 patients with C1-INH antigen levels equal to or “slightly” less than 50% of normal should have been diagnosed with type I, instead of type II (despite other family members having type II). Most importantly, most countries do not have access to the functional assay and diagnosis depends on elevated C1-INH levels and low C4; however, the latter test is neither sensitive nor specific, thus leading to underdiagnosis of type II HAE. Studies using genetic testing frequently documented novel SERPING1 variants, underscoring the allelic heterogeneity of HAE type I/II and that the spectrum of genotypic variability underlying this condition is not yet fully understood. While genetic testing is often viewed as a definitive and confirmative measure for diagnosing HAE type I/II, it must be acknowledged that pathogenic variants of SERPING1 may not be detected in up to 20% of symptomatic patients with deficient C1-INH levels and/or function [29]. This may be due to factors that modify SERPING1 expression, including defects in intronic or untranslated regions, as well as environmental variables [72]. This emphasizes the importance of accounting for and integrating clinical/laboratory/genetic findings for diagnosing type I/II, particularly in epidemiological studies estimating prevalence and/or incidence. Genetic testing, although known to have low sensitivity [3, 73], is recommended for diagnosing HAE-nC1-INH given the current lack of conventional laboratory tests for this subtype [52, 54]. Nevertheless, a physician survey in the US reported a heavy reliance on the response to HAE-specific medications as a diagnostic tool (74%), with under a half (43%) using genetic tests for F12 or other genes (PLG, 5%; ANGPT1, 4%; KNG1, 2%). The low usage rate of genetic tests for HAE-nC1-INH has been attributed to limited accessibility, testing being only available for 4 of 8 normal HAE types, and insufficient awareness of genetic testing among physicians; high costs and lack of medical insurance coverage may also be important factors [15, 43]. By complementing earlier reviews and addressing key methodological limitations, this review advanced the evidence base on HAE prevalence through a more comprehensive, type-specific, and quality-informed synthesis. A major strength of this review was the use of a comprehensive and sensitive search strategy, resulting in the identification of more relevant records (n = 41) compared to previous reviews that identified 6 to 24 studies [8–10]. Second, prior reviews have been limited by the lack of pooled global and regional estimates [8, 10]. While Fisch et al. [9] reported pooled estimates, these did not account for HAE type; notably, HAE cases reported via the Swedish national registry for patients with HAE (Sweha-Reg) [36, 74] and UK Primary Immunodeficiency (UKPID) [41, 42] registry may also have been double-counted (across publications) in the pooled estimate. Third, this review utilized a quality assessment tool [14] specifically designed to evaluate prevalence studies. These assessments were used to inform a selective approach, thereby excluding studies with weaker methodology from the pooled estimates. Although Fisch et al. [9] conducted a quality assessment, the results were not used to guide study inclusion in their pooled estimates; furthermore, the assessment tool used (National Heart, Lung, and Blood Institute Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies [75]) did not account for methodological features (e.g., representativeness of sampling frame, case ascertainment methods) critical to prevalence studies. A limitation of the included studies was the heterogeneity in population sources (e.g., clinical centers, hospital registries, surveys). Furthermore, all studies utilized a referral center approach, whereby prevalence estimates were based on data collected from specialized centers or registries in which individuals with HAE were likely to have been treated or reported. The lack of true population-based studies that survey a random or representative sample of the general population may be ascribed to the high costs and logistical challenges when investigating rare conditions such as HAE. While a referral center approach is more feasible and cost-effective, it is also likely to underestimate true prevalence due to the lack of referral or registry reporting, as well as the existence of asymptomatic patients. Estimates may also be skewed due to the overrepresentation of certain referral centers and heterogeneity across studies in terms of resources available to engage with a larger number of centers and perform additional screening of family members [35]. Prevalence estimates may also have been underestimated, particularly in younger age-groups, due to diagnostic delay, which differed substantially across countries/regions. Therefore, estimates reported in this review should be viewed as “minimal” estimates. Another limitation was a lack of data from low- to middle-income countries. Further studies in these regions are required to determine HAE prevalence rates and the extent to which these are affected by the avoidance of medical care (e.g., due to cultural and social stigma) and lack of available diagnostic tools and therapies. Finally, the use of different thresholds for determining deficiencies in C1-INH level and function, inconsistent reference to established guidelines and reporting of diagnostic methodology (e.g., laboratory assays used, sample storage parameters, repeat testing), inherent differences in sensitivities/specificities of functional assays used, and the variable use of genetic testing hindered comparisons of prevalence estimates across studies. Notably, although most studies specifying laboratory criteria for HAE diagnosis also reported the use of functional tests, one study commented on the current lack of functional assays for clinicians across South Africa [50]; while serum samples can be shipped to European laboratories for testing, this is both costly and logistically complex [50]. A more practical approach in regions without access to functional assays may be the use of low C4 and elevated C1-INH levels to screen for type II HAE, which has been shown to have positive and negative predictive values of 100% and 82.9%, respectively [76]. Conclusions This review determined pooled, minimal diagnosed annual prevalence estimates of 1.31/100,000 for type I HAE, 0.20/100,000 for type II HAE, 0.06/100,000 for HAE-nC1-INH, and 1.70/100,000 for type I/II/nC1-INH combined. While the pooled estimate for European countries (1.64/100,000) was relatively higher than that for North American countries, as well as individually reported estimates in other regions, valid comparisons across countries are hindered by a large degree of heterogeneity in data sources and diagnostic methodology. Additional, high-quality studies using standardized diagnostic methods are required to elucidate whether regional differences can be truly attributed to ethnic differences in phenotypic and genotypic variability. Statement of Ethics This study did not require ethics approval as it was based solely on the review and synthesis of previously published literature. No human participants, identifiable data, or unpublished confidential information were involved; therefore, approval from an Ethics Committee was not necessary. Written informed consent was not required for this study because it did not involve human participants, individual-level data, or collection of primary data. Conflict of Interest Statement T.J.C. reports the receipt of grants or contracts from Astria, CSL Behring, Pharvaris, Ionis Pharmaceuticals, ADARx, KalVista, Intellia, Takeda, and Biomarin; consulting fees from Kalvista, BioCryst, CSL Behring, Takeda, Pharvaris, Intellia, ADARx, and Ionis Pharmaceuticals; payment or honoraria from Grifols, KalVista, CSL Behring, and Takeda; participation on a data safety monitoring board or advisory board for CSL Behring, Takeda, KalVista, Pharvaris, ADARx, Ionis Pharmaceuticals, Intellia, and Astria; leadership or fiduciary role for ACARE International HAE Center and HAE-A Advisory Board. M.A.R. reports the receipt of grants or contracts from Astria, BioCryst, Biomarin, CSL Behring, Intellia, Ionis Pharmaceuticals, KalVista, Pharvaris, and Takeda; consulting fees from BioCryst, Biomarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis Pharmaceuticals, KalVista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, and Takeda; payment or honoraria from BioCryst, CSL Behring, Grifols, Pharming, and Takeda; and leadership or fiduciary role for US HAE Association Medical Advisory Board and Immune Deficiency Foundation Physician Advisory Board. T.D.S. reports the receipt of grants or contracts from Ionis Pharmaceuticals. E.K. reports employment with Evidinno Outcomes Research Inc. O.L.T.L. reports employment with Evidinno Outcomes Research Inc. M.R.M. reports employment and stock or stock options with Ionis Pharmaceuticals. Funding Sources This study was funded by Ionis Pharmaceuticals, Inc. (United States). Ionis Pharmaceuticals commissioned the study and was involved in the study conception and design. The sponsor reviewed the study protocol, study results, and manuscript. The authors retained responsibility for study execution, data analysis, interpretation of results, manuscript preparation, and the decision to submit the manuscript for publication. Author Contributions Conceptualization: T.J.C., M.A.R., T.D.S., and M.R.M.; methodology: E.K., O.L.T.L., and M.R.M.; formal analysis, investigation: E.K. and O.L.T.L.; writing – original draft: O.L.T.L.; writing – review and editing: T.J.C., M.A.R., T.D.S., E.K., O.L.T.L., and MRM; and all authors reviewed and approved the manuscript.